Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/30/18
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 07/01/22
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 06/25/21
End: 04/30/26
Due: 04/30/27
Phase: N/A
Priority: Normal
Start: 03/02/23
End: 12/31/26
Due: 12/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma | NCT03569995 | Won Seog Kim | user2@example.com | None | 2018-11-30 | 2025-06-30 | 2026-06-30 | - | - | 2025-07-14 |
| Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) | NCT05230680 | Won Seog Kim | user2@example.com | None | 2022-07-01 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |
| Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy | NCT04763616 | Won Seog Kim | user2@example.com | None | 2021-06-25 | 2026-04-30 | 2027-04-30 | - | - | 2025-07-14 |
| Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type | NCT05477264 | Won Seog Kim | user2@example.com | None | 2023-03-02 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |